The CEO driven by lentiviral vector success

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jon Alberdi, CEO at VIVEbiotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jon, covering:

• Falling in love with the world of management and its role in influencing people and society
• Why, after 12 years in the B2B automotive sector, did he decide to jump into the life science space?
• His first impressions of the sector and the viral vector space, and why he saw nothing but potential to industrialize
• The before and after of a PE deal with Ampersand - speed, challenge, and intensity
• Riding the growth of CAR-T products, and which therapy areas are driving demand

Graduating in Economics from the University of the Basque Country - Sarriko, Bilbao, he received complementary education in management and leadership. His professional career is closely tied to the Financial Function of several companies operating in diverse sectors, including investment banking, sports service management, and the automotive and aftermarket industries. In 2008, he joined the global industrial public company GKN, where he held several financial controlling roles, including the R&D department at the worldwide product development centre.

He later moved to Germany to take on the responsibility of Financial Direction for a global business unit of GKN, where he stayed for five years until he joined VIVEbiotech, gaining a solid background in management within an international environment.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.